News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ironwood Pharmaceuticals (IRWD) Receives Notice Of Allowance For Methods Of Use Formulation Patent Expected To Extend LINZESS® Patent Protection Through 2031



2/10/2014 9:52:27 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application covering methods of using LINZESS® (linaclotide) to treat patients with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). The patent application, co-owned by Ironwood and Forest Laboratories, Inc., is expected to issue in mid-2014 and extend LINZESS patent protection into 2031.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES